Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE-2: Orforglipron vs dapagliflozin in type 2 diabetes on metformin
2023-507206-13-00Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of orforglipron in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in HbA1c. Started Mar 2024; status: completed.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2023-507206-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507206-13-00.